Introduction {#sec1-1}
============

Critical illness polyneuropathy and critical illness myopathy are frequent complications of severe illness involving both motor and sensory axons. Critical illness polyneuropathy and myopathy usually present as flaccid and symmetric paralysis\[[@ref1][@ref2]\], which is seen in approximately 25--45% of critically ill patients who are admitted to intensive care units\[[@ref3]\]. Limb (mostly from the lower extremities) and respiratory muscle weakness manifested by patients with critical illness polyneuropathy and myopathy often causes prolonged intensive care unit stays and mechanical ventilator dependence, in addition to increased long-term disability\[[@ref4]\]. Weaning off mechanical ventilators is associated with problems attributed to involvement of the phrenic nerves, diaphragm, and intercostal and other accessory respiratory muscles\[[@ref5]\]. Although rare, facial muscles can also be involved\[[@ref6]\], ophthalmoplegia may occur\[[@ref5]\]. Results from a multicenter Italian critical illness myopathy and/or neuropathy study showed that critical illness myopathy had a better prognosis compared with critical illness polyneuropathy\[[@ref7]\]. Many patients continue to suffer from decreased exercise capacity and compromised quality of life for months to years after the acute event\[[@ref7]\]. Recently, substantial progress has been made in the understanding of the pathophysiology of critical illness polyneuropathy and myopathy\[[@ref1][@ref2][@ref3]\]. Both antiseptic prophylaxis and control of hyperglycemia may be effective for the prevention of critical illness polyneuropathy and myopathy; aggressive treatment of sepsis and multiple organ failure are considered to be the most effective measures to reduce the incidence\[[@ref1][@ref2][@ref3]\].

Critical illness polyneuropathy and myopathy: history and risk factors {#sec1-2}
======================================================================

Neuromuscular dysfunction in the intensive care unit setting has attracted attention for over a century as it leads to high morbidity and poor prognosis\[[@ref8]\]. Limb and respiratory muscle weakness in critically ill patients was initially attributed to catabolic myopathy and diaphragmatic fatigue, when it was firstly described in 1892 by Osler\[[@ref8]\]. Later, in 1961, Mertens\[[@ref9]\] demonstrated coma-related disseminated neuropathy and suggested metabolic and ischemic lesions of peripheral nerves as basic pathophysiological mechanisms. The term "critical illness polyneuropathy" was introduced in 1984 by Bolton et al.\[[@ref10]\] who attributed characteristic axonal loss of motor and sensory fibers to the toxic effect of sepsis. Critical illness myopathy, which has been increasingly recognized from the 1990s, can be elicited from excessive dosages of intravenous corticosteroids\[[@ref11]\]. Increasing evidence in intensive care units has shown that critical illness polyneuropathy and myopathy frequently occur concomitantly\[[@ref12]\].

Critical illness polyneuropathy affects more than one third of the most severe critically ill patients\[[@ref13][@ref14]\]; the percentage increases when associated with acute respiratory distress syndrome\[[@ref15]\], sepsis, or systemic inflammatory response syndrome\[[@ref16]\] and reaches up to 100% when further complicated by multiple organ failure\[[@ref17]\]. Critical illness myopathy is present in 36% of those who need mechanical ventilation for severe asthma\[[@ref18]\], and approximately 70% of patients who are admitted to intensive care units for at least 7 days, while most patients have critical illness polyneuropathy concomitantly\[[@ref19]\]. However, the epidemiology tends to correlate with the duration and the severity of basic diseases\[[@ref5][@ref15][@ref20][@ref21][@ref22]\].

As mentioned above, acute respiratory distress syndrome, sepsis, systemic inflammatory response syndrome, and multiple organ failure are the most common factors associated with either critical illness polyneuropathy or myopathy or a combination of both\[[@ref14][@ref23][@ref24]\]. Prolonged bed rest, medication, and infections, are major risk factors for critical illness polyneuropathy and myopathy. In particular, gram-negative bacteremia is an independent risk factor for the development of critical illness polyneuropathy or myopathy. Hyperglycemia has also been identified as an independent risk factor\[[@ref25]\], with important potential effects in terms of prevention\[[@ref26]\]. Other less consistent risk factors include hyperpyrexia, hyperosmolality, hypoalbuminemia, hypoxia, hypotension, hyper/hypocalcemia, female sex, old age, severe illness, central neurologic failure such as septic encephalopathy, long duration of organ dysfunction, renal failure and renal replacement therapy, parenteral nutrition, vasopressor and catecholamine support, and septic encephalopathy\[[@ref16][@ref24][@ref27][@ref28][@ref29][@ref30][@ref31]\].

Pathophysiology of critical illness polyneuropathy and myopathy {#sec1-3}
===============================================================

Animal models have shown evidence of channelopathies in both critical illness polyneuropathy and myopathy, and human studies also identified axonal degeneration in critical illness polyneuropathy and myosin loss in critical illness myopathy\[[@ref34][@ref35]\]. The causes of axonal degeneration of sensory and motor axons in critical illness polyneuropathy, and atrophy and necrosis of myofibers in critical illness myopathy are complex and not fully understood; they possibly involve microcirculatory abnormality, metabolic derangements, reversible channelopathy, and bioenergetic dysfunction\[[@ref36]\] ([Figure 1](#F1){ref-type="fig"}). Microvascular alterations including increased expression of E-selectin, vasodilatation, increased permeability of capillaries, extravasation, endoneural edema and hypoxemia; metabolic alterations including production of cytokines and other toxic factors, hyperglycemia, hormone imbalance, hypoalbuminemia, amino acid deficiency and activation of proteolytic pathways; electrical alterations including ion channel dysfunction, cell depolarization, inexcitability, altered Ca^2+^ homeostasis and changes in excitation-contraction coupling; and bioenergetic failure including anti-oxidant depletion, reactive oxygen species increase, mitochondrial dysfunction, and apoptosis, all contribute independently, simultaneously, or synergistically to a combination of ischemic and cytopathic hypoxia and energy depletion, which eventually leads to critical illness polyneuropathy and myopathy\[[@ref13][@ref24]\]. Sepsis-related disturbances of the microcirculation in peripheral nerves and muscles, and the resultant production of cytokines, may increase the permeability of the microvasculature and further exacerbate hypoxemia and energy depletion\[[@ref37]\]. Hyperglycemia\[[@ref25]\], decreased ratio of anabolic/catabolic hormones\[[@ref38]\], lower total amino acid levels\[[@ref39]\], and hypoalbuminemia\[[@ref5]\] can further increase endoneurial edema, which contributes to muscle weakness. Proteolytic pathways including calpain\[[@ref40]\], lysosomal pathways, the ubiquitin-proteasome pathway\[[@ref41][@ref42]\], and transforming growth factor-β/mitogen-activated protein kinase pathways are up-regulated by inflammation and stress stimuli, inducing the breakdown of proteins (mainly by myofibrillar proteins such as actin and myosin), which are processed by the proteasome pathway\[[@ref43][@ref44][@ref45][@ref46]\]. Electrodiagnostic studies showed that sodium channels\[[@ref47][@ref48][@ref49][@ref50][@ref51]\] and sarcoplasmic reticulum calcium release\[[@ref35]\] play a vital role in muscle membrane hypoexcitability or inexcitability. The peripheral nerves of patients with critical illness polyneuropathy are depolarized, and membrane depolarization is related to endoneurial hyperkalemia or hypoxia, or both\[[@ref52][@ref53]\].

![Pathogenesis of critical illness polyneuropathy (CIP) and myopathy (CIM).\
The pathogenesis of CIP and CIM is complex, involving microcirculatory changes, metabolic alterations, electrical abnormalities, and bioenergetic failure. They contribute independently, simultaneously, or synergistically to the pathogenesis of CIP and CIM. ROS: Reactive oxygen species.](NRR-9-101-g001){#F1}

Acquired channelopathy involving voltage-dependent sodium channels and decreased expression of nitric oxide synthases results in hypoexcitability or inexcitability of muscle cell membranes\[[@ref52]\]. Nitric oxide over-production is also associated with prolonged respiratory failure as it increases reactive oxygen species. Additionally, the immune system affects critical illness polyneuropathy and myopathy as proinflammatory and anti-inflammatory cytokines are released from infiltrating leukocytes in skeletal muscle\[[@ref40][@ref41][@ref42]\]. Moreover, a thus far unknown low molecular weight neurotoxic agent has been identified in the serum of critical illness polyneuropathy patients. Specifically, an *in vitro* toxicity assay showed serum neurotoxicity in 12 of 16 patients with critical illness polyneuropathy\[[@ref54]\]. A decreased ratio of anabolic/catabolic hormones contributes to myofilament loss and apoptosis\[[@ref13]\]. Endogenous corticosteroid concentrations are temporarily increased at the beginning, but drop during the later phase because of adrenal insufficiency\[[@ref55]\].

Evaluation and diagnostic criteria for critical illness polyneuropathy and myopathy {#sec1-4}
===================================================================================

The Medical Research Council sum score can be used as an initial diagnostic measure of muscle force in conscious patients who are suspected of having critical illness polyneuropathy or myopathy. Critical illness polyneuropathy and myopathy are arbitrarily diagnosed if the Medical Research Council sum score is less than 48\[[@ref56]\]. Further investigations, including serum creatine kinase level, electromyography, and muscle biopsy provide more reliable information for diagnosis\[[@ref5]\]. Elevation of creatine kinase levels is associated with muscle necrosis, but is not of diagnostic use on its own due to low sensitivity\[[@ref5]\]. Electromyography, however, is an essential method in making a final or differential diagnosis. A reduction in the amplitude of compound muscle action potentials or sensory nerve action potentials, or both, with preserved conduction velocity and normal distal motor latencies, in addition to normal responses to repetitive nerve stimulation, may be seen within 2--5 days after the onset of symptoms\[[@ref57]\]. The reduction in amplitude often precedes clinical presentation and accompanying fibrillation potentials and positive sharp waves that may occur in the second or third week\[[@ref15][@ref58][@ref59]\]. The duration of compound muscle action potentials is an important indicator of critical illness myopathy, and it accompanies the fall in amplitude\[[@ref11][@ref19][@ref60]\]. Compound muscle action potential duration can be 2--3 times longer compared with healthy controls, and is most pronounced in lower limb nerves. Electrophysiological screening showing compound muscle action potential duration reductions below two standard deviations of the normal value accurately identifies patients with critical illness polyneuropathy and myopathy\[[@ref61]\]. Patients admitted for sepsis/systemic inflammatory response syndrome showing electromyographic signs of characteristic compound muscle action potentials in early stages, and an abnormal baseline nerve conduction study are more likley to develop acquired neuromuscular dysfunction with increased hospital mortality\[[@ref62]\]. Baum et al.\[[@ref63]\] identified four different clusters of electrophysiological impairment in patients with sepsis/systemic inflammatory response syndrome, which enabled further differentiation of the severity of neuromuscular disturbances in sepsis-associated organ failure (Cluster 1: normal values for compound muscle action potentials, sensory nerve action potential, and nerve conduction velocity in all nerves, which accounted for 10% of total patients; Cluster 2: pathological values for compound muscle action potentials in the lower extremities and other parameters normal, which accounted for 17% of patients; Cluster 3: moderate pathological values for compound muscle action potentials, sensory nerve action potential, and sensory nerve conduction velocity in upper and lower extremities and motor nerve conduction velocity in lower extremities, which accounted for 40% of patients; Cluster 4: severe disturbances of compound muscle action potentials, sensory nerve action potential, and nerve conduction velocity in upper and lower extremities, which accounted for 33% of patients).

Varying degrees of fibrillation potentials and positive sharp waves can be recorded in both critical illness polyneuropathy and myopathy. Direct muscle stimulation is able to distinguish neuropathy from myopathy\[[@ref24][@ref64][@ref65]\]. Critical illness myopathy is characterized by significant slowing of the muscle fiber conduction velocity, or even muscle fiber conduction block during the acute phase, which correlates with prolonged compound muscle action potentials duration and altered muscle fiber excitability\[[@ref35]\]. Abnormal sensory nerve action potentials are characteristic for critical illness polyneuropathy, although local edema may interfere with optimal sensory nerve stimulation and recording\[[@ref19][@ref63][@ref65][@ref66][@ref67]\].

Muscle biopsy is still considered the gold standard for confirming muscle involvement in the disease process despite its invasiveness\[[@ref11][@ref21]\]. Critical illness myopathy is pathologically classified into five subtypes: (1) thick filament myopathy; (2) acute myopathy with scattered necrosis; (3) acute myopathy with diffuse necrosis; (4) disuse cachectic myopathy; and (5) rhabdomyolysis ([Figure 2](#F2){ref-type="fig"})\[[@ref13][@ref60]\]. Although unusual, myopathy can progress to frank rhabdomyolysis\[[@ref13][@ref68][@ref69]\]. Critical illness polyneuropathy presents as morphological signs of axonal degeneration in both type 1 and type 2 fibers, resulting in extensive denervation atrophy of muscles\[[@ref57]\]. During recovery, muscle biopsy may show grouped atrophy of muscle fibers\[[@ref57]\]. Furthermore, angular atrophy of isolated scattered muscle fibers has been observed as part of an acute denervation process\[[@ref37][@ref46][@ref57][@ref70][@ref71]\].

![Pathological classification of critical illness polyneuropathy (CIP) and myopathy (CIM).](NRR-9-101-g002){#F2}

Clinical characteristics and examination results should be carefully evaluated for correct diagnosis of critical illness polyneuropathy and myopathy\[[@ref2][@ref13][@ref46][@ref70][@ref71]\]. A definite diagnosis of critical illness polyneuropathy requires that the following criteria be met: (1) The critically ill patient develops limb weakness or difficulty in weaning, after non-neuromuscular causes such as heart and lung diseases have been excluded; (2) electromyography shows axonal motor and sensory polyneuropathy; (3) absent decremental response to repetitive nerve stimulation\[[@ref13]\]. A definite diagnosis of critical illness myopathy requires that the following criteria be met: (1) The critically ill patient develops limb weakness or difficulty weaning, after non-neuromuscular causes such as heart and lung diseases have been excluded; (2) compound muscle action potential amplitudes are less than 80% of the normal lower limit in two or more nerves without conduction block; (3) sensory nerve action potential amplitudes are greater than 80% of the normal lower limit; (4) needle electromyography shows short duration, low-amplitude motor unit potentials with early or normal full recruitment, with or without fibrillation potentials, in conscious and collaborative patients, or increased compound muscle action potential duration or reduced muscle membrane excitability on direct muscle stimulation in non-collaborative patients; (5) absent decremental response to repetitive nerve stimulation; (6) muscle histopathology shows primary myopathy\[[@ref13]\]. Subsequently, a diagnostic flowchart for critical illness polyneuropathy and myopathy has been proposed by Latronico and Bolton\[[@ref13]\].

Electromyography and nerve conduction studies are theoretically sufficient for clinical diagnosis\[[@ref72]\]. However, electrophysiological studies are difficult to conduct in intensive care units due to the presence of edema, inadequate voluntary muscle contraction, and electrical interference\[[@ref73]\]. Thus, electrophysiological diagnosis of critical illness polyneuropathy and myopathy is often only possible when patients are fully cooperative, and when nerve conduction studies are performed without interference\[[@ref73]\]. Additionally, coexistence of critical illness polyneuropathy and myopathy may make interpretation difficult. Thus, electrophysiological findings should always be correlated with clinical findings. In difficult cases, muscle biopsy may be required for a definite diagnosis. Recently, Tzanis et al.\[[@ref74]\] have proposed that maximum inspiratory pressure may serve as a surrogate indicator for the assessment of critical illness polyneuropathy and myopathy. The authors measured maximum inspiratory pressure using the unidirectional valve method, independent of the patient\'s ability to cooperate. A significant correlation was found between maximum inspiratory pressure and the Medical Research Council scale score (*r* = 0.68, *P* \< 0.001)\[[@ref74]\]. The findings indicated that maximum inspiratory pressure, estimated using the unidirectional valve method, may be useful for early detection of intensive care unit-acquired weakness\[[@ref74]\].

Differential diagnoses {#sec1-5}
======================

Differential diagnoses of acute neuromuscular weakness commonly include Guillain-Barré syndrome, metabolic neuropathies, toxic neuropathies, and neuropathies due to nutritional deficiencies.

Guillain-Barré syndrome, an autoimmune disease of the peripheral nervous system, usually presents as symmetric, progressive, and ascending paralysis, sensory abnormalities and areflexia, and 30% of patients require mechanical ventilation\[[@ref75]\]. The prototype of Guillain-Barré syndrome, which accounts for 90% of all Guillain-Barré syndrome cases in Europe and North America, is acute inflammatory demyelinating polyneuropathy. The axonal variants of Guillain-Barré syndrome demyelinating polyneuropathy, acute motor axonal neuropathy and acute motor-sensory axonal neuropathy, however, are more prevalent in Asia and South and Central America. The nine most common clinical subtypes of Guillain-Barré syndrome are shown in [Table 1](#T1){ref-type="table"}.

###### 

Clinical subtypes of Guillain-Barré syndrome

![](NRR-9-101-g003)

Different patterns of Guillain-Barré syndrome are probably due to the diverse interaction between antibodies and T cells of divergent specificities\[[@ref76]\]. Differentiating critical illness polyneuropathy from Guillain-Barré syndrome, especially the axonal variants, may be difficult on purely clinical grounds, as Guillain-Barré syndrome is known for its variable atypical manifestations\[[@ref77]\].

The nerve conduction velocity test shows decreased velocity in typical Guillain-Barré syndrome, whereas normal conduction velocity and decreased action potential, both features of axonal neuropathy, can be seen in critical illness-polyneuropathy and in axonal variants of Guillain-Barré syndrome\[[@ref58]\]. The major clinical difference between critical illness polyneuropathy and axonal variants of Guillain-Barré syndrome is that critical illness polyneuropathy is part of a critical illness and it usually occurs during the stay in intensive care, whereas, axonal Guillain-Barré syndrome is a severe form of Guillain-Barré syndrome, which leads to intensive care unit admission\[[@ref15]\]. Differentiation between Guillain-Barré syndrome and critical illness polyneuropathy is essential for the determination of therapeutic strategies, as intravenous immunoglobulin or plasma exchange is required in Guillain-Barré syndrome\[[@ref77]\], while supportive care is needed in critical illness polyneuropathy\[[@ref13]\]. Onset of clinical signs and electrophysiological changes in peripheral nerves and muscles during the development of critical illness polyneuropathy and myopathy can be rapid\[[@ref13][@ref17][@ref21][@ref78]\]. Albuminocytologic dissociation in cerebrospinal fluid can help differentiate between the two diseases. The cerebrospinal fluid protein concentrations in patients with Guillain-Barré syndrome are usually normal at the beginning of the disease, and increase in over 90% of patients by the end of the second week\[[@ref79]\], whereas protein concentrations are usually unchanged in critical illness polyneuropathy and myopathy. Furthermore, a nerve biopsy and detection of anti-ganglioside antibodies could be helpful in differentiating critical illness polyneuropathy from axonal Guillain-Barré syndrome\[[@ref15]\]. The criteria for differentiation are specified in [Table 2](#T2){ref-type="table"}\[[@ref80][@ref81]\].

###### 

Differentiation between critical illness polyneuropathy (CIP) and Guillain-Barré syndrome
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Ionic abnormalities such as hypokalemia, hypophosphatemia, and hypermagnesemia, in addition to the use of several drugs including neuromuscular blocking agents, cancer chemotherapy, statins, and anti-retrovirals, should be differentiated because each can affect neuromuscular transmission and cause muscle weakness\[[@ref13]\]. Propofol infusion syndrome, a syndrome involving severe metabolic acidosis, cardiac failure, rhabdomyolysis, renal failure, and hypertriglyceridemia after high-dose propofol (5 mg/kg/h) administration for long periods (\> 48 hours), is also seen in intensive care units and should be taken into consideration\[[@ref82]\]. Propofol infusion syndrome is a rare, but often fatal, syndrome described in critically ill children\[[@ref82]\]. Recently, several cases have been reported in adults as well\[[@ref82]\]. High-dose propofol, but also supportive treatments using catecholamines and corticosteroids, can act as triggering factors\[[@ref82]\].

Treatment and prognosis of critical illness polyneuropathy and myopathy {#sec1-6}
=======================================================================

Thus far, no specific therapy and only preventive and supportive measures have been shown to be beneficial in the management of critical illness polyneuropathy and myopathy. The measures include aggressive treatment of sepsis, reduction of dose and duration of neuromuscular blocking agents and corticosteroids\[[@ref36]\], rehabilitation programs and careful positioning, nutritional interventions\[[@ref4]\], anti-oxidant therapy\[[@ref83]\], testosterone derivates\[[@ref84]\], growth hormones, and immunoglobulins\[[@ref28][@ref33]\] ([Figure 3](#F3){ref-type="fig"}).

![Therapeutic strategies for critical illness polyneuropathy (CIP) and myopathy (CIM).\
Supportive measures include nutritional interventions, anti-oxidant therapies, hormone replacement, and immunoglobulins. Intensive insulin therapy improves blood glucose control, and independently reduces the incidence of CIP and CIM. Early rehabilitation combining mobilization with physiotherapy is also advisable.](NRR-9-101-g005){#F3}

As hyperglycemia is a risk factor for critical illness polyneuropathy and myopathy, strict glycemic control with insulin should have a beneficial effect on patients. Studies have shown that intensive insulin therapy for hyperglycemia lowered the risk of critical illness polyneuropathy and myopathy, and decreased time on ventilatory support, the duration of intensive care unit stay, and the 180-day mortality rate\[[@ref85][@ref86]\]. Insulin is associated with some potential beneficial effects, including anti-inflammatory effects\[[@ref87]\], endothelial protection\[[@ref88]\], improvement of dyslipidemia, and neuroprotective effects in animals\[[@ref89]\], and is also an anabolic hormone\[[@ref5]\]. A Cochrane systematic review of 825 critically ill patients enrolled in two trials reported that the incidence of critical illness polyneuropathy and/or myopathy was significantly reduced after intensive insulin therapy\[[@ref31]\]. Despite its effectiveness, intensive insulin therapy increases the risk of hypoglycemia. Data from other studies challenged the use of intensive insulin therapy, indicating that strict glycemic control may increase mortality among adults\[[@ref90]\]. In a large international randomized trial published in the New England Journal of Medicine, 3,054 critically ill patients were assigned to undergo strict glycemic control (with a target blood glucose range of 4.5--6.0 mmol/L) and 3,050 underwent conventional control (with a target blood glucose range of ≤ 10.0 mmol/L). The investigators found that strict glycemic control increased mortality among adults in intensive care units. Additionally, a blood glucose target of ≤ 10.0 mmol/L resulted in lower mortality compared with a target of 4.5--6.0 mmol/L\[[@ref90]\]. Other studies have indicated that the incidence of weakness or failure to wean did not decrease, and that no improvement in muscle strength was achieved by strict glycemic control\[[@ref76][@ref91]\].

Early rehabilitation combining mobilization with physiotherapy is emerging as an important strategy to treat critical illness polyneuropathy and myopathy, and to facilitate and improve long-term recovery\[[@ref24][@ref86][@ref92]\] and functional independence of patients, and shorten the duration of ventilation and hospitalization\[[@ref93][@ref94]\]. Electrical muscle stimulation is a form of exercise and mobilization that does not require patients' active participation, and can thus be applied to immobilized patients\[[@ref95]\]. Electrical muscle stimulation has been shown to be beneficial to patients with chronic heart failure\[[@ref96]\] and chronic obstructive pulmonary disease\[[@ref97][@ref98]\], as well as intensive care unit and hospital inpatients\[[@ref99][@ref100][@ref101]\]. Briefly, the protocol of electrical muscle stimulation (45 Hz, 400 µs, 12 seconds on and 6 seconds off, 0.8 second ramp up/ramp down duration) was implemented simultaneously on the vastus lateralis, vastus medialis, and peroneus longus of both lower extremities. Rectangular electrodes were placed on the motor points of the aforementioned muscle groups of both legs, and amplitude was set at levels able to cause visible contractions. During the session, the angle of the patients' knee joint was approximately 40° (0° corresponds to full knee extension). Electrical muscle stimulation sessions lasted for 55 minutes, including 5-minute warm-up and 5-minute recovery periods\[[@ref95]\]. A recent study has suggested that electrical muscle stimulation can reduce the loss of muscle mass and exert an acute beneficial effect on the microcirculation, thereby reducing the incidence of critical illness polyneuropathy and myopathy and favorably affecting muscle strength\[[@ref95]\]. In a randomized controlled study\[[@ref95]\], 142 consecutive patients, with an acute physiology and chronic health evaluation II score of ≥ 13, were randomly assigned to electrical muscle stimulation or control groups. Electrical muscle stimulation was applied daily to the vastus lateralis, vastus medialis, and peroneus longus of both lower extremities. Various muscle groups were evaluated using the Medical Research Council scale for muscle strength\[[@ref95]\]. Their results showed that patients in the electrical muscle stimulation group achieved higher Medical Research Council scores compared with controls in wrist flexion, hip flexion, knee extension, and ankle dorsiflexion, indicating that the electrical muscle stimulation group performed better in the legs and overall\[[@ref95]\]. They concluded that electrical muscle stimulation has beneficial effects on the strength of critically ill patients, mainly affecting the muscle groups stimulated, but it may also affect unstimulated muscle groups suggesting a potential effective means of muscle strength preservation and early mobilization in this patient population\[[@ref95]\]. Electrical muscle stimulation is beneficial to patients who cannot actively exercise, increases muscle strength, and has positive effects on tissue healing and regional vascularization\[[@ref102][@ref103]\]. Electrical muscle stimulation is also safe, tolerable, and can be easily applied even in patients unable to cooperate.

Both active and passive therapeutic exercises are recommended as soon as patients are hemodynamically stable, to not only improve neuromuscular function and reduce disability, but also to reduce oxidative stress and inflammation\[[@ref104]\]. In addition, early mobilization or kinesiotherapy provides faster recovery to function and reduces weaning and hospitalization time\[[@ref105]\]. An early mobility and walking program provides guidelines that can assist clinicians who work with patients in intensive care units, especially those receiving mechanical ventilation\[[@ref105]\]. The program may facilitate the development of a treatment plan with a focus on individual functional capability, progressive mobilization, and early walking activities. Early mobility in intensive care units can lead to positive outcomes for patients including minimizing complications of bed rest, promoting improved function, promoting weaning from ventilatory support as patients' overall strength and endurance improves, reducing duration of hospital stay, reducing overall hospital costs, and improving quality of life\[[@ref105]\]. Prolonged stays in intensive care units and mechanical ventilation are associated with functional decline and increased morbidity, mortality, cost of care, and length of hospital stay. Implementation of an early mobility and walking program could have a beneficial effect on all of the above factors. The program encompasses progressive mobilization and walking procedures, with the progression based on a patient\'s functional capability and ability to execute the prescribed activity. The program is divided into four phases. Each phase involves guidelines on positioning, therapeutic exercises, transfers, walking reeducation, and duration and frequency of mobility sessions. The goal in phase 1 is to start mobilization as soon as the patient\'s medical condition is stable. Phase 1 includes critically ill patients who are in unstable condition at times and are restricted to bed rest. They can only be out of bed in a stretcher chair because of their inability to bear weight. Phase 2 includes patients whose overall medical condition and muscle strength allow standing activities. These patients progress to transfer training with a walker, prewalking activities, and walking reeducation because of their limited endurance and weakness. Phase 3 involves patients who are ready to start a progressive walking reeducation program and functional training outside the room to improve endurance and functional mobility. Phase 4 involves patients who no longer require ventilatory support and/or have been transferred out of the intensive care unit and are being prepared for hospital discharge\[[@ref105]\]. Execution of this program requires a collaborative effort among members of the multi-disciplinary team to coordinate, care for, and provide safe mobilization of patients in intensive care units. It is advisable to initiate rehabilitation as early as possible once diagnosis is established\[[@ref106][@ref107]\].

Future therapeutic interventions should be targeted at proinflammatory cytokines, free radical pathways, muscle gene expression, ion channel function, and proteolytic muscle protein mechanisms\[[@ref108]\]. The retrospective chart analysis in Mohr et al.\[[@ref109]\] suggested that early application of intravenous immunoglobulins may prevent or mitigate critical illness polyneuropathy. However, this awaits confirmation in large randomized-controlled studies. Schols and colleagues found that nutritional supplementation in combination with a short course of nandrolone decanoate may enhance the gain in respiratory muscle function in depleted patients with chronic obstructive pulmonary disease, without causing adverse effects\[[@ref84]\].

Attention to critical illness polyneuropathy and myopathy outside intensive care units {#sec1-7}
======================================================================================

Critical illness polyneuropathy and myopathy outside the usual setting of the intensive care unit has also attracted attention\[[@ref110]\]. There are no precise estimates regarding critical illness polyneuropathy or myopathy outside intensive care units; figures are anecdotal and likely influenced by intensive care unit admission and discharge policies, and hospital resources\[[@ref110][@ref111]\]. However, as Latronico and Rasulo\[[@ref110]\] proposed, there are two reasons why critical illness polyneuropathy and myopathy outside the intensive care unit merits closer attention. On one hand, critical illness is a functional diagnosis, which is not related to a specific environment. In contrast, the onset of critical illness polyneuropathy and/or myopathy can occur early in critical illness, even before intensive care unit admission. Critical illness polyneuropathy and myopathy are not routinely assessed during the intensive care unit stay, so the diagnosis of critical illness polyneuropathy and myopathy is limited\[[@ref110][@ref112]\]. As a consequence, clinicians may need to treat patients with critical illness polyneuropathy or myopathy after intensive care unit discharge.

Conclusions {#sec1-8}
===========

In summary, critical illness polyneuropathy and myopathy are frequent complications that occur in patients in intensive care units, especially among those who have acute respiratory distress syndrome, sepsis, systemic inflammatory response syndrome, and/or multiple organ failure. This review has attempted to outline the current understanding of critical illness polyneuropathy and myopathy, and underscores the importance of differentiating critical illness polyneuropathy and myopathy from Guillain-Barré syndrome. A guided approach to diagnosis of critical illness polyneuropathy and myopathy is recommended. However, assessment of weakness, polyneuropathy, or myopathy in the intensive care unit setting is sometimes difficult. Presently, the only possible way to reduce the incidence of critical illness polyneuropathy and myopathy is to control risk factors. Both preventive and supportive therapies may be beneficial. Avoiding or limiting the use of neuromuscular blocking agents and corticosteroids, as well as early rehabilitation combining mobilization with physiotherapy is crucial to patients' prognosis. Further investigations are needed to explore effective preventive, diagnostic, and therapeutic strategies for treatment of critical illness polyneuropathy and myopathy.
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